Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4924-4932

  Chen, Youjun ^a   Clark, Suzanna ^a   Wong, Terence ^a   Chen, Yongmei ^a   Chen, Yvonne ^a   Dennis, Mark S ^a   Luis, Elizabeth ^a   Zhong, Fiona ^a   Bheddah, Sheila ^a   Koeppen, Hartmut ^a   Gogineni, Alvin ^a   Polakis, Paul ^a   Mallet, William ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; MUCIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCULATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG TOLERABILITY; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; RAT; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; CA-125 ANTIGEN; FEMALE; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, SCID; OVARIAN NEOPLASMS; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250379434     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4512     Document Type: Article

References (26)

1. American Cancer Society, Inc. Cancer facts and figures. Atlanta (GA): American Cancer Society; 2007.
2. Bast RC, Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
3. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984;50:765-9.
4. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 1983;79:98-104.
5. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348-66.
6. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-5.
7. Nicodemus CF, Berek JS. Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther 2005;5:87-96.
8. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292-302.
9. Berek JS, Taylor PT, Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22:3507-16.
10. Sabbatini P, Dupont J, Aghajanian C, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006;12:5503-10.
11. Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol 2005;5:382-7.
12. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003;52:328-37.
13. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
14. Chui CJ, Grimaldi JC, Milton S, Yan M, Yi S, inventors. Amplification-based cloning method. United States patent 6,607,889. 2003.
15. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001;276:6591-604.
16. Mao W, Luis E, Ross S, et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 2004;64:781-8.
17. Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220-39.
18. Institute of Laboratory Animal Resources, "Guide for the Care and Use of Laboratory Animals", (NIH Publication #85-23). Washington (DC): National Academy Press; 1996.
19. Hamilton TC, Young RC, McKoy WM, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379-89.
20. Hamilton TC, Young RC, Louie KG, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 1984;44:5286-90.
21. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
22. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003:21:778-84.
23. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540-7.
24. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
25. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-9.
26. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.